Aquestive Therapeutics In... (AQST)
3.01
-0.20 (-6.23%)
At close: Mar 28, 2025, 3:59 PM
3.02
0.33%
After-hours: Mar 28, 2025, 07:42 PM EDT
Aquestive Therapeutics Balance Sheet Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
| Cash & Equivalents | 71.55M | 23.87M | 27.27M | 28.02M | 31.81M | 49.33M | 60.6M | 17.38M | 9.21M |
| Short-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Long-Term Investments | n/a | n/a | 5M | 6M | 7M | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 4.22M | 5.44M | 6.45M | 6.9M | 7.84M | n/a | 239K | 1.24M | 630K |
| Receivables | 7.34M | 8.47M | 4.7M | 12.12M | 6.96M | 13.13M | 6.48M | 6.18M | 10.82M |
| Inventory | 6.04M | 6.77M | 5.78M | 4.04M | 2.46M | 2.86M | 5.44M | 4.01M | 2.89M |
| Other Current Assets | 3.29M | 1.85M | 2.13M | 6.15M | 6.8M | 6M | 3.36M | 591K | 420K |
| Total Current Assets | 88.22M | 40.97M | 39.89M | 47.26M | 44.63M | 68.31M | 74.2M | 28.16M | 23.33M |
| Property-Plant & Equipment | 8.98M | 9.74M | 7.9M | 7.78M | 10.32M | 9.73M | 12.21M | 13.46M | 15.12M |
| Goodwill & Intangibles | n/a | 1.28M | 1.44M | 51K | 102K | 439K | 204K | 254K | 305K |
| Total Long-Term Assets | 13.2M | 16.45M | 15.79M | 14.73M | 18.26M | 10.16M | 12.65M | 14.95M | 16.06M |
| Total Assets | 101.42M | 57.42M | 55.67M | 61.99M | 62.88M | 78.48M | 86.85M | 43.12M | 39.39M |
| Account Payables | 10.29M | 8.93M | 9.95M | 8.31M | 7.09M | 12.27M | 20.44M | 9.6M | 6.64M |
| Deferred Revenue | 1.05M | 1.55M | 1.51M | 765K | 693K | 806K | 721K | 1.35M | 802K |
| Short-Term Debt | 536K | 412K | 18.95M | 2.92M | 3.3M | n/a | 4.6M | n/a | n/a |
| Other Current Liabilities | 6.63M | 7.08M | 8.79M | 9.61M | 9.7M | 5.17M | 4.29M | 4.06M | 3.37M |
| Total Current Liabilities | 18.86M | 18.31M | 39.68M | 21.96M | 21.1M | 18.55M | 32.95M | 15.35M | 10.81M |
| Long-Term Debt | 37.47M | 32.91M | 102.64M | 112.56M | 84.7M | 60.34M | 42.6M | 45.51M | 38.65M |
| Other Long-Term Liabilities | 105.25M | 80.34M | 2.03M | 2.48M | 1.95M | 1.36M | 1.22M | 8.75M | 7.51M |
| Total Long-Term Liabilities | 142.72M | 145.6M | 134.55M | 122.16M | 90.28M | 66.05M | 43.82M | 54.26M | 46.16M |
| Total Liabilities | 161.58M | 163.91M | 174.23M | 144.13M | 111.38M | 84.6M | 76.77M | 69.61M | 56.97M |
| Total Debt | 38M | 33.32M | 56.09M | 56.42M | 40.48M | 60.34M | 47.2M | 45.51M | 38.65M |
| Common Stock | 91K | 69K | 55K | 41K | 35K | 34K | 25K | 12.73M | 11.24M |
| Retained Earnings | -363.21M | -319.08M | -311.21M | -256.8M | -186.26M | -130.47M | -61.38M | -120.09M | -108.67M |
| Comprehensive Income | n/a | n/a | n/a | n/a | n/a | n/a | -35.19M | -32.01M | -28.25M |
| Shareholders Equity | -60.16M | -106.49M | -118.55M | -82.13M | -48.5M | -6.12M | 10.08M | -26.5M | -17.58M |
| Total Investments | n/a | 4M | 5M | 6M | 7M | n/a | n/a | n/a | n/a |